Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 21037024.
- Also identified by DOI 10.1158/1078-0432.CCR-10-2658.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Blockade of the CTLA-4 and PD-1 inhibitory pathways in T cells via the administration of neutralizing antibodies at the time of interleukin (IL)-15 therapy markedly enhanced the survival of tumor-bearing mice as compared with those receiving IL-15 alone or IL-15 in combination with just one of the antibodies.
Medical subject headings
- Antibodies, Neutralizing
- Immune Tolerance
- Interleukin-15
- Neoplasms